Soligenix, Inc. SNGX Company Overview
Soligenix, Inc. SNGX Current Price and Quotes
Last Price 2.03
Previous Close 2.01 Open 2.04
Daily Range 2.04 - 1.91 52wk Range 2.48 - 0.43
Volume 58,129 Dividend N/A
Average Vol (3m) 82,282 Yield N/A
SNGX Stock Message Board http://investorshangout.com/search?q=SNGX&...mp;yt1=Go!
Last Updated: Tuesday, October 29, 2013 02:31:58 AM
Soligenix, Inc. SNGX
Company Information
29 Emmons Drive
Suite C-10
Princeton, NJ 08540
Website: http://www.soligenix.com
Phone: 609-538-8200
Soligenix, Inc. SNGX
Soligenix, Inc. is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host dis...
Soligenix, Inc. SNGX
Financial Reportings and Disclosures
Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jun 30, 2013 10-Q
CIK 0000812796
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o Jun 10, 2013
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Christopher J. Schaber President, CEO
Joseph M. Warusz Vice President, Acting CFO, Principal Acct. Officer
Company Directors
Keith Brownlie
Gregg Lapointe
Robert Rubin
Jerome Zeldis
Company Notes
Formerly=DOR BioPharma, Inc. until 9-2009
Formerly=Endorex Corp. until 12-01
Formerly=ImmunoTherapeutics, Inc. until 9-96
Service Providers
Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available
Soligenix, Inc. SNGX
SNGX Security Details
Share Structure
Market Value1 $38,631,889 a/o Oct 28, 2013
Shares Outstanding 19,030,487 a/o Aug 07, 2013
Float Not Available
Authorized Shares 50,000,000 a/o Jun 07, 2013
Par Value 0.001
Shareholders
Shareholders of Record 940 a/o Feb 26, 2013
Security Notes
New Issue=6-87 500,000 shs in units (1 sh Com & 1 Class A Warr 7-31-92) at $4 per unit by Seaboard Planning Corp.
Note=4-18-06 deleted from AMEX
Capital Change=shs decreased by 1 for 15 split Pay date=06/11/1997.
Capital Change=shs decreased by 1 for 20 split. Pay date=02/01/2012.
Short Selling Data
Short Interest 358,964 (3.8%)
Sep 30, 2013
Significant Failures to Deliver No
Transfer Agent(s)
American Stock Transfer & Trust Company
Soligenix, Inc. SNGX Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Total Revenue 3,145 7,663 1,948 2,816
Cost of Revenue 2,593 2,108 1,638 1,484
Gross Profit 552 5,555 309 1,332
Operating Expenses
Research and Development 2,609 6,273 5,986 4,523
Sales, General and Admin. 2,633 2,242 2,201 2,860
Non-Recurring Items - - - -
Other - - - -
Operating Income (4,691) (2,960) (7,878) (6,051)
Income From Continuing Operations
Add'l Income/Expense Items 6 7 247 20
Earnings Before Interest and Tax (4,684) (2,953) (7,632) (6,032)
Interest Expense - - 1 3
Earnings Before Tax (4,684) (2,953) (7,632) (6,034)
Income Tax (521) (574) (246) -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (4,163) (2,379) (7,387) (6,034)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (4,163) (2,379) (7,387) (6,034)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (4,163) (2,379) (7,387) (6,034)
Soligenix, Inc. SNGX Recent News
Oct 28, 2013 Soligenix to Host Conference Call and Webcast Discussion on Oral Mucositis
Oct 21, 2013 Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
Oct 17, 2013 Soligenix Announces Formation of International Melioidosis Scientific Advisory Board
Oct 3, 2013 Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
Sep 25, 2013 Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield(TM) in GI ARS
Sep 19, 2013 Soligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield(TM) in GI ARS
Sep 16, 2013 FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
Sep 5, 2013 Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
Aug 12, 2013 Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments
SNGX Soligenix, Inc. Research DD Guide
Stock Message Board http://investorshangout.com/search?q=SNGX&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/SNGX/quote
Stock Chart http://www.otcmarkets.com/stock/SNGX/chart
Company Info http://www.otcmarkets.com/stock/SNGX/company-info
Recent News http://www.otcmarkets.com/stock/SNGX/news
Financials http://www.otcmarkets.com/stock/SNGX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/SNGX/filings
Short Sales http://www.otcmarkets.com/stock/SNGX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/SNGX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/SNGX/research
Summary http://finance.yahoo.com/q?s=SNGX
Historical Prices http://finance.yahoo.com/q/hp?s=SNGX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=SNGX
Basic Chart http://finance.yahoo.com/q/bc?s=SNGX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=SNGX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=SNGX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=SNGX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=SNGX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=SNGX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=SNGX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=SNGX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=SNGX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=SNGX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=SNGX
Balance Sheet http://finance.yahoo.com/q/bs?s=SNGX
Cash Flow http://finance.yahoo.com/q/cf?s=SNGX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/SNGX
Market Watch http://www.marketwatch.com/investing/stock/SNGX
Bloomberg http://www.bloomberg.com/quote/SNGX:US
Morningstar http://quotes.morningstar.com/stock/s?t=SNGX
Bussinessweek http://investing.businessweek.com/research/st...icker=SNGX
Barchart http://www.barchart.com/quotes/stocks/SNGX
OTC Short Report http://otcshortreport.com/index.php?index=SNGX
Investopedia http://www.investopedia.com/markets/stocks/SNGX/?wa=0
List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Soligenix, Inc. SNGX Current Price and Quotes
Last Price 2.03
Previous Close 2.01 Open 2.04
Daily Range 2.04 - 1.91 52wk Range 2.48 - 0.43
Volume 58,129 Dividend N/A
Average Vol (3m) 82,282 Yield N/A
SNGX Stock Message Board http://investorshangout.com/search?q=SNGX&...mp;yt1=Go!
Last Updated: Tuesday, October 29, 2013 02:31:58 AM
Soligenix, Inc. SNGX
Company Information
29 Emmons Drive
Suite C-10
Princeton, NJ 08540
Website: http://www.soligenix.com
Phone: 609-538-8200
Soligenix, Inc. SNGX
Soligenix, Inc. is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host dis...
Soligenix, Inc. SNGX
Financial Reportings and Disclosures
Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jun 30, 2013 10-Q
CIK 0000812796
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o Jun 10, 2013
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Christopher J. Schaber President, CEO
Joseph M. Warusz Vice President, Acting CFO, Principal Acct. Officer
Company Directors
Keith Brownlie
Gregg Lapointe
Robert Rubin
Jerome Zeldis
Company Notes
Formerly=DOR BioPharma, Inc. until 9-2009
Formerly=Endorex Corp. until 12-01
Formerly=ImmunoTherapeutics, Inc. until 9-96
Service Providers
Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available
Soligenix, Inc. SNGX
SNGX Security Details
Share Structure
Market Value1 $38,631,889 a/o Oct 28, 2013
Shares Outstanding 19,030,487 a/o Aug 07, 2013
Float Not Available
Authorized Shares 50,000,000 a/o Jun 07, 2013
Par Value 0.001
Shareholders
Shareholders of Record 940 a/o Feb 26, 2013
Security Notes
New Issue=6-87 500,000 shs in units (1 sh Com & 1 Class A Warr 7-31-92) at $4 per unit by Seaboard Planning Corp.
Note=4-18-06 deleted from AMEX
Capital Change=shs decreased by 1 for 15 split Pay date=06/11/1997.
Capital Change=shs decreased by 1 for 20 split. Pay date=02/01/2012.
Short Selling Data
Short Interest 358,964 (3.8%)
Sep 30, 2013
Significant Failures to Deliver No
Transfer Agent(s)
American Stock Transfer & Trust Company
Soligenix, Inc. SNGX Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Total Revenue 3,145 7,663 1,948 2,816
Cost of Revenue 2,593 2,108 1,638 1,484
Gross Profit 552 5,555 309 1,332
Operating Expenses
Research and Development 2,609 6,273 5,986 4,523
Sales, General and Admin. 2,633 2,242 2,201 2,860
Non-Recurring Items - - - -
Other - - - -
Operating Income (4,691) (2,960) (7,878) (6,051)
Income From Continuing Operations
Add'l Income/Expense Items 6 7 247 20
Earnings Before Interest and Tax (4,684) (2,953) (7,632) (6,032)
Interest Expense - - 1 3
Earnings Before Tax (4,684) (2,953) (7,632) (6,034)
Income Tax (521) (574) (246) -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (4,163) (2,379) (7,387) (6,034)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (4,163) (2,379) (7,387) (6,034)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (4,163) (2,379) (7,387) (6,034)
Soligenix, Inc. SNGX Recent News
Oct 28, 2013 Soligenix to Host Conference Call and Webcast Discussion on Oral Mucositis
Oct 21, 2013 Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
Oct 17, 2013 Soligenix Announces Formation of International Melioidosis Scientific Advisory Board
Oct 3, 2013 Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
Sep 25, 2013 Soligenix Awarded NIAID Contract Valued up to $6.4 Million for the Development of OrbeShield(TM) in GI ARS
Sep 19, 2013 Soligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield(TM) in GI ARS
Sep 16, 2013 FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
Sep 5, 2013 Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
Aug 12, 2013 Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments
SNGX Soligenix, Inc. Research DD Guide
Stock Message Board http://investorshangout.com/search?q=SNGX&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/SNGX/quote
Stock Chart http://www.otcmarkets.com/stock/SNGX/chart
Company Info http://www.otcmarkets.com/stock/SNGX/company-info
Recent News http://www.otcmarkets.com/stock/SNGX/news
Financials http://www.otcmarkets.com/stock/SNGX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/SNGX/filings
Short Sales http://www.otcmarkets.com/stock/SNGX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/SNGX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/SNGX/research
Summary http://finance.yahoo.com/q?s=SNGX
Historical Prices http://finance.yahoo.com/q/hp?s=SNGX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=SNGX
Basic Chart http://finance.yahoo.com/q/bc?s=SNGX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=SNGX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=SNGX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=SNGX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=SNGX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=SNGX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=SNGX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=SNGX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=SNGX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=SNGX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=SNGX
Balance Sheet http://finance.yahoo.com/q/bs?s=SNGX
Cash Flow http://finance.yahoo.com/q/cf?s=SNGX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/SNGX
Market Watch http://www.marketwatch.com/investing/stock/SNGX
Bloomberg http://www.bloomberg.com/quote/SNGX:US
Morningstar http://quotes.morningstar.com/stock/s?t=SNGX
Bussinessweek http://investing.businessweek.com/research/st...icker=SNGX
Barchart http://www.barchart.com/quotes/stocks/SNGX
OTC Short Report http://otcshortreport.com/index.php?index=SNGX
Investopedia http://www.investopedia.com/markets/stocks/SNGX/?wa=0
List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
